Expert panel advises treatment choices for young people with returning blood cancers
Experts advise treatment choices for children and young adults with returning blood cancers.
Plain-language title generated from the registry record
Registry title: International Leukemia Target Board
Key facts
- Where
- Barcelona, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people whose blood cancer has come back or has not responded to treatment, and who have no standard treatment left. Their case is discussed by an expert board that gives advice.
- Age
- Under 18 at first diagnosis and under 25 when joining the trial (record lists 0 to 25 years).
- Sex
- All sexes can join.
- Disease stage
- Blood cancer (hematological malignancy) that has come back (relapsed) or has not responded to treatment (refractory). No current standard of care treatment is available.
- Earlier treatment
- Treated in a pediatric or young adult setting or study protocol, with no current standard of care treatment.
- Biomarker or test result
- Tumor molecular profiling results and flow cytometry results from a certified lab must be available.
Main reasons for not taking part
- Life expectancy shorter than 6 weeks
- No written informed consent from the patient and/or parents or guardians
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 25 years old?
- What type of cancer has the patient been diagnosed with?
- Is this cancer newly diagnosed, or has it come back or not responded to treatment?
Source: NCT05270096, who can take part
Where in Spain
- Vall d'HebronBarcelona, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Princess Maxima Center for Pediatric Oncology
- Trial code
- NCT05270096
- Record updated
- 9 January 2026
- Original description
The iLTB is a proof-of-concept initiative for children with r/r hematological malignancies, in which available treatment options will be prioritized by actionable events in a harmonized and uniform setting across Europe by a team of biologists, bio-statisticians, bio-informaticians, disease experts, geneticists, flow-experts, clinical trial physicians and also the treating physician.Read full original descriptionShow less
International Concerted Action to Allocate Children, Adolescents and Young Adults With Relapsed and Refractory Leukemia/Lymphoma to the Right Therapy.
The iLTB is a proof-of-concept initiative for children with r/r hematological malignancies, in which available treatment options will be prioritized by actionable events in a harmonized and uniform setting across Europe by a team of biologists, bio-statisticians, bio-informaticians, disease experts, geneticists, flow-experts, clinical trial physicians and also the treating physician.
The iLTB will discuss molecular (genetic lesions), immunophenotypic/surface antigen markers information and, if available, drug response profiles to prioritize these events taking into account the treatment history and treatment intention (bridging to hematopoietic stem cell transplanation/CAR-T or palliative) of each patient followed by a registry to monitor how often iLTB advice has been followed, which other therapy was chosen (off-label, compassionate use) and what the patient outcome is at an aggregated level.
As such the iLTB is non-interventional as it mainly provides advice and registers data on patients discussed in the iLTB.
Inclusion: The patient has been diagnosed with a R/R hematological malignancy; The patient is less than 18 years of age at the time of first diagnosis and less than 25 years at the time of inclusion with relapse/refractory hematological malignancy; The patient is treated in a pediatric/AYA setting or study protocol, with no current standard of care treatment; The patients' life expectancy is at least 6 weeks; The patient has undergone any sort of molecular profiling of his/her tumor and the re-sults of this analysis are available; The patient has undergone flow cytometry in a certified lab and results are available; Written informed consent of patient and/or parent(s)/guardian(s) to discuss the patient in the iLTB according to local law and legislation has been obtained.